<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462148</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00032807</org_study_id>
    <nct_id>NCT02462148</nct_id>
  </id_info>
  <brief_title>Perineural Steroids for Peripheral Nerve Blocks</brief_title>
  <official_title>Perineural Steroids for Saphenous Peripheral Nerve Blocks: An Equivalency Dosing Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the efficacy of dexamethasone for prolongation of peripheral nerve
      blocks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, double-blinded, placebo-controlled trial is to examine if
      dexamethasone given perineurally as an adjuvant to the nerve block will prolong the time to
      recovery from sensory nerve block from a saphenous (or adductor canal) nerve block. The
      primary outcome will be time to resolution of the nerve block as assessed by pinprick over
      the saphenous nerve distribution. If this primary end point is met, this study will also
      serve as an equivalency dosing study comparing 1 mg of perineural dexamethasone to 4 mg of
      perineural dexamethasone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Sensory Nerve Block</measure>
    <time_frame>24 to 36 hours</time_frame>
    <description>The primary outcome will be time to resolution of the nerve block as assessed by pinprick over the saphenous nerve distribution. Testing will occur every two hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal Pain Scores</measure>
    <time_frame>24 to 36 hours</time_frame>
    <description>Verbal Pain Scores will be compared between groups as obtained every six hours during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Post Operative Nausea and Vomiting</measure>
    <time_frame>24 to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic Complications</measure>
    <time_frame>Indefinite</time_frame>
    <description>Each patient will be followed for neurologic complications (paresthesias, etc) if they should occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Opioid Use and Consumption</measure>
    <time_frame>24-36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid analgesic request</measure>
    <time_frame>24 to 36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Used in nerve block mixture</description>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <other_name>Dexamethasone Sodium Phosphate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Used in nerve block mixture</description>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Bupivacaine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Used in nerve block mixture</description>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saphenous Peripheral Nerve Block</intervention_name>
    <description>Peripheral nerve block.</description>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Adductor Canal Peripheral Nerve Block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective robotic medial MAKO partial knee arthroplasty

          -  agreed to a regional anesthesia technique

        Exclusion Criteria:

          -  contraindications to regional anesthesia

          -  presence of a progressive neurological deficit

          -  a pre-existing coagulopathy, infection

          -  insulin and non-insulin dependent diabetes mellitus

          -  systemic use of corticosteroids within 30 days of surgery

          -  chronic use of an opioid analgesic (&gt;3 months or a combined total of more than 40 mg
             Oxycodone equivalents a day)

          -  pregnancy

          -  a prior history of an adverse event (for example: psychosis) or an allergy to
             dexamethasone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl S Henshaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Anesthesia, Conduction</keyword>
  <keyword>Anesthesia, Local</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Saphenous</keyword>
  <keyword>Adductor Canal</keyword>
  <keyword>Nerve Block</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Preanesthetic Medication</keyword>
  <keyword>Perioperative Period</keyword>
  <keyword>Peripheral Nerve Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

